| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| IntraBiotics Pharmaceuticals, Inc. |
| 1255 Terra Bella Avenue, Mountain View, CA 94043 * (650) 526-6800 |
| Business Description | The company develops and intends to commercialize new antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases. |
| Offering Information Company has | |||
| Trading As | IBPI (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 1/27/00 |
| Domestic Shares Offered | 7,500,000 | Offer Date | 3/27/00 |
| Foreign Shares Offered | 0 | Filing Range | $13.00 - $15.00 |
| Company Shares | 7,500,000 | Offer Price | $15.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.050 |
| Gross Proceeds | $112,500,000 | Selling | $0.630 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 28,580,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Deutsch Banc Alex. Brown | Lead Manager | (410) 727-1700 |
| Adams, Harkness & Hill | Co-manager | (617) 371-3705 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Warburg Dillon Read LLC | Co-manager | (203) 719-3000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | ||
| Revenues | - | - | 5.507 | 6.357 | 7.863 | - | - |
| Income from Oper. | -2.863 | -4.998 | -4.556 | -18.173 | -24.321 | - | - |
| Net Income | -2.822 | -4.816 | -4.075 | -17.382 | -23.115 | - | - |
| E.P.S | -14.250 | -11.920 | -6.390 | -20.890 | -21.620 | - | - |
| Revenue Growth (%) | - | - | 15.43 | 23.690 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -24.72 | - | - | ||||
| Cash Flow - Inv. | -15.09 | - | - | ||||
| Cash Flow - Fin. | 28.80 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 35.96 | Current Assets | 32.06 | Current Ratio | 5.07 |
| Total Liab. | 8.04 | Current Liab. | 6.32 | Debt Ratio | 22.37% |
| Total Equity | 27.91 | Working Cap. | 25.74 | Debt to Equity Ratio | 0.29 |
| Cash | 18.86 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for clinical trials, development and scale-up of manufacturing processes by our contract manufacturers, research and development activities, acquisition of new technologies or products, working capital and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Latham & Watkins |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Entities affiliated with The Sprout Group | 17.30 | |
| Investor (Guernsey) Ltd. | 15.30 | |
| Entities affiliated with Spinnaker Technology | 13.10 | |
| Entities affiliated with St. Paul Venture Capital Inc. | 9.20 | |
| New York Life Insurance Company | 5.80 | |
| Note: represents ownership of 5% or more prior to the offering. | ||